Healthcare Triangle Will launch QuantumNexis With Planned Strategic Acquisitions of Niyama and Ezovion to Lead the Future of Gen AI-Powered Healthcare SaaS
PLEASANTON, CALIF. - May 27, 2025 ( NEWMEDIAWIRE ) - Healthcare Triangle, Inc. (Nasdaq: HCTI) ('HCTI' or the 'Company'), a visionary leader in digital transformation solutions for the healthcare and life sciences industries, today announced a transformative expansion with the launch of QuantumNexis, Inc. ('QuantumNexis'), a new subsidiary focused on AI-powered SaaS solutions for the global healthcare market. This strategic move will be executed through the simultaneous acquisitions by QuantumNexis of Niyama Healthcare, a pioneer in AI-driven digital mental wellness, and Ezovion Solutions, a leading provider of smart hospital and EHR management platforms.
QuantumNexis will serve as the innovation engine for HCTI's recurring revenue business lines. By integrating Niyama's personalized Gen AI mental health technology with Ezovion's hospital intelligence platform, the new subsidiary is poised to address urgent global demands in clinical efficiency, mental health accessibility, and healthcare automation.
Niyama Healthcare: Transforming Mental Health with Gen AI & Clinical Intelligence
Niyama Healthcare delivers a fully digital, evidence-based mental wellness platform that integrates holistic medicine. At its core is a proprietary Generative AI engine that personalizes treatment using 360-degree analytics across psychological, physical, and behavioral data. The platform supports psychiatry, clinical psychology, medical yoga, and nutrition - all accessible via mobile or desktop and currently has piloted over 5000 clients. This scalable approach meets the rising demand for flexible, AI-assisted mental healthcare. ( www.niyama.ai ).
Ezovion Solutions: Smarter AI-based Hospital Information System
Ezovion Solutions offers a modular, cloud based AI-powered hospital information system (HIS) that connects care workflows across diagnostics, medications, EHR, and revenue cycle management (RCM). Built on FHIR/HL7-compliant infrastructure, Ezovion empowers hospitals to deliver smarter, real-time care through advanced analytics, AI-driven decision support, and enhanced operational visibility across clinical and administrative functions. Ezovion solutions are deployed over 325 hospitals across Asia and MEA ( www.ezovion.com ).
'QuantumNexis marks a pivotal step in our growth strategy by separating our Gen AI SaaS innovation from traditional services,' said Sujatha Ramesh, Chief Operating Officer of HCTI. 'With Niyama and Ezovion, we're launching an intelligent, global healthcare platform that delivers measurable impact at scale.'
'This structure unlocks significant valuation upside,' added David Ayanoglou, Chief Financial Officer. 'By isolating our fastest-growing business into QuantumNexis, we are improving transparency, enhancing capital strategy, and positioning HCTI for long-term shareholder value creation.'
The launch of QuantumNexis establishes HCTI as a focused player in Gen AI healthcare SaaS, delivering powerful solutions to underserved markets while enabling margin expansion through automation and product-led growth. This move reaffirms the company's commitment to innovation, financial discipline, and sustainable market leadership.
About Healthcare Triangle (HCTI)
Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz(TM) and DataEz(TM). HITRUST's Risk-based, 2-year (r2) certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. www.healthcaretriangle.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995), and include, among others, statements regarding the consummation of the private placement, satisfaction of the customary closing conditions of the private placement and the use of the proceeds therefrom. Such forward-looking statements include our expectations and those statements that use forward-looking words such as 'projected,' 'expect,' 'possibility' and 'anticipate.' The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors out lined in the company's annual report on form 10-K for the year ended December 31, 2024, on file with the Securities Exchange Commission (the 'SEC') and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
Investors:
1-800-617-9550
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
an hour ago
- Yahoo
Boeing posts smaller loss as jet deliveries rise
(Reuters) -Boeing reported a smaller second-quarter loss on Tuesday as the U.S. planemaker ramped up jet production and deliveries, recovering from a regulatory crisis and a major strike that halted most production last year. Shares of the company rose 1.5% in premarket trading. After years of grappling with quality issues and production delays on its flagship 737 MAX, Boeing has cautiously ramped up monthly output this year. In May, the company produced 38 737s. Production has been stable since then, according to the company. "As we continue to execute our Safety & Quality Plan, there's more stability in our operations," CEO Kelly Ortberg said in a letter to Boeing employees on Tuesday. The U.S. Federal Aviation Administration had capped the production of Boeing's best selling 737 MAX jets following a mid-air panel blowout in a nearly new jet in January 2024. "We plan to seek FAA approval to increase to rate 42 when our key performance indicators (KPIs) show that we're ready," Ortberg added. It has delivered 206 737 MAX jets through the first half of the year. Wall Street closely tracks aircraft deliveries, because planemakers collect much of their payment when they hand over jets to customers. Boeing also increased 787 production at its plant in Charleston, South Carolina, from five aircraft a month to seven a month. Through the first half of the year, the planemaker has booked 668 orders, or 625 net orders after cancellations and conversions. An improvement in deliveries marks a pivotal step in Boeing's effort to rebound from years of production disruptions and crises that piled on debt, highlighting the urgency of accelerating output to restore financial stability. The planemaker posted a net loss of $612 million, or 92 cents per share, for the quarter through June, compared with $1.44 billion, or $2.33 per share, a year earlier. However, the planemaker continues to face pressure from supply chain disruptions that have delayed production and limited its ability to meet surging aerospace demand. It posted a loss of nearly $12 billion in 2024 due to challenges across its major business units including charges on its defense programs. It also remains exposed to U.S. President Donald Trump's sweeping tariffs, which could increase parts costs and further strain an already fragile supply chain. Boeing's revenue for the quarter through June rose 35% to $22.75 billion. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Earnings, Trade Outlook Lift Wall Street Pre-Bell; Asia Mixed, Europe Up
Wall Street futures again pointed to fresh all-time records pre-bell Tuesday, as traders digested a Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
